

Hypochlorous Acid

Livestock

Identification of Petitioned Substance

1

2

3 **Chemical Names:** Hypochlorous acid, 14 Clean Smart, FloraFresh® Floral Quality Care
4 hypochloric(I) acid, chloranol, 15 Solution, HSP2O Pro Disinfectant

5 hydroxidochlorine **CAS Numbers:** 7790-92-3

6 **Other Name:** Hydrogen hypochlorite, **Other Codes:** European Community Number-
7 Chlorine hydroxide 22757, IUPAC-Hypochlorous acid

8 **Trade Names:** Oculus Puracyn Antimicrobial List other codes: PubChem CID 24341

9 Skin and Wound Cleanser, Vashe® Wound InChI Key: QWPPOHNGKGFJK-

10 Therapy Solution (OTC use), Vashe® Wound UHFFFAOYSA-N

11 Therapy Solution (Professional use), UNII: 712K4CDC10

12 Nixall™ Wound and Skin Care (OTC and

13 Professional use), Excelyte VET,

Summary of Petitioned Use

16

17 A petition was received by the National Organic Program (NOP) requesting the addition of
18 hypochlorous acid (HOCl) generated from electrolyzed water to section 205.603 of the National List:
19 synthetic substances allowed for use in organic livestock production. HOCl is petitioned for use as a
20 disinfectant, and medical and topical treatments for organic livestock production. Direct HOCl contact
21 with animals is requested. HOCl is the active ingredient in commercial veterinary and farm products used
22 for wound care, post milking teat sanitation, dermatological disease and the treatment of eye irritation.

23 Recently, the National Organic Standards Board (NOSB) considered a petition to allow HOCl from
24 electrolyzed water for use in organic crop and livestock production and handling and passed three
25 separate recommendations for its addition to the National List in sections 205.601(a)(2), 205.603(a)(7) and
26 205.605(b). In a memorandum responding to this recommendation, NOP indicated its intent to move
27 forward with a proposed rule for public comment to add HOCl to the National List. At the time of this
28 report, a proposed rule has not yet been published. While these sections apply to the use of chlorine
29 materials including HOCl respectively in crops for preharvest use and sprout production, in livestock for
30 disinfecting and sanitizing facilities and equipment and in handling for disinfecting and sanitizing food
31 contact surfaces where residual chlorine remains below the maximum residual disinfectant limit, currently
32 4 milligrams/liter, the previous NOSB recommendations did not consider the direct contact of HOCl with
33 organic livestock (US NOP, 2015).

34 This limited scope technical evaluation report requested by the NOSB will both supplement information
35 contained in a previous technical evaluation report and provide additional information pertaining to the
36 use of HOCl in direct contact with livestock for organic production, specifically its use for the treatment of
37 keratoconjunctivitis (pinkeye) and wounds.

Characterization of Petitioned Substance

38

Composition of the Substance:

39

40 HOCl is an oxyacid of chlorine containing monovalent chlorine that acts as an oxidizing or reducing agent
41 (NCBI, 2017). A 2015 technical report on [HOCl \(handling/processing uses\)](#) is available at the NOP
42 Petitioned Substances Database. HOCl is a chlorine releasing agent. It is one of three forms of aqueous
43 chlorine: chlorine gas (Cl₂), HOCl and hypochlorite ion (OCl⁻). Mostly HOCl is present in aqueous
44 solutions pH between 2 - 7.5 at 25°C (Kettle et al., 2014).

45

46

47 **Source or Origin of the Substance:**

48 HOCl is produced by electrolyzing a brine solution made with purified water and sodium chloride. In
 49 general, the brine is submitted to direct electrical current as it flows through a cell that allows the physical
 50 separation of solutions around the positive and negative electrodes. Separation is usually achieved with a
 51 semi-permeable membrane. At pH 3.5 – 6.5 (30°C), greater than ninety percent of the chlorine species
 52 present at the anode is HOCl. If the flow cell is constructed properly HOCl can be removed from the anodic
 53 compartment as it is produced. Sodium hydroxide produced at the cathode is separately removed.

54 Dakin's solution, a solution containing a low concentration of sodium hypochlorite (household bleach),
 55 boric acid and sodium bicarbonate was adopted in the early 1900s and is still used as an effective
 56 microbiocide and disinfectant for burns and wounds (Dakin, 1915a,b). HOCl at a concentration of 0.3
 57 percent is the predominant chlorine releasing agent present in Dakin's solution. Dakin's solution is not
 58 produced electrolytically. It is effective in killing *Staphylococcus* spp., *Streptococcus* spp. and *E. coli* (Smith et
 59 al., 1915). The effectiveness of Dakin's solution and the presence of HOCl is pH dependent. Although
 60 Dakin's solution is not produced from electrolyzed water, it is still a source of pure HOCl.

61 **Properties of the Substance:**

62 There is a pH and temperature dependent equilibrium between the three aqueous chlorine species, Cl₂,
 63 OCl⁻ and HOCl. This relationship for selected values of pH and temperature is shown for HOCl and OCl⁻
 64 (Table 1). Of the three aqueous species, HOCl is the primary bactericidal agent (White, 1972). As the pH
 65 increases the percentage of HOCl decreases with an increase in the percentage of OCl⁻. With increasing
 66 ionic strength, the percentage of HOCl present in solution also decreases. At pH 7.5, with other ions such
 67 as phosphate present in solution the amount of HOCl in solution can be as low as 51%, balanced by 49%
 68 OCl⁻ (White, 2011).

Table 1 Percentage of chlorine present as HOCl as a function of pH and temperature (assuming zero ionic strength and considering HOCl and OCl⁻ as the only chlorine species present)

pH	Percent HOCl						
	0°C	5°C	10°C	15°C	20°C	25°C	30°C
5.0	99.85	99.82	99.80	99.77	99.74	99.71	99.68
5.5	99.53	99.45	99.36	99.27	99.18	99.09	99.00
6.0	98.53	98.27	98.00	97.72	97.45	97.18	96.92
6.5	95.48	94.72	93.94	93.14	92.35	91.58	90.86
7.0	86.99	85.02	83.05	81.11	79.24	77.48	75.86
7.5	67.89	64.23	60.78	57.59	54.69	52.11	49.84
8.0	40.06	36.21	32.89	30.04	27.63	25.60	23.91
8.5	17.45	15.22	13.42	11.95	10.77	9.81	9.04

Adapted from Black and Veatch Corporation, 2011

69

70 **Specific Uses of the Substance:**

71 HOCl is the active microbiocidal ingredient in a number of veterinary preparations used for treatment of
 72 infectious keratoconjunctivitis (pinkeye), burns, wounds and mastitides. Keratoconjunctivitis is an
 73 inflammation of the covering membrane of the eye, including the orbit and the inner surface of the eyelids.
 74 This inflammation typically extends below the conjunctival layer (Farley, 1941). There are several causative

75 agents. In cattle the most significant cause is the bacterium *Moraxella bovis*, and to a lesser extent *Chlamydia*
76 *spp.*, *Neisseria catarrhalis*, and *Mycoplasma spp.* In sheep, the causes are *Rickettsia conjunctivae*, *Neisseria*
77 *catarrhalis*, *Mycoplasma conjunctivae*, *Acholeplasma oculi* and *Chlamydia spp.* In goats, the cause is *Rickettsia*
78 *conjunctivae*. In pigs, the cause is *Rickettsia spp.* In horses, the cause is frequently viral, but bacteria such as
79 *Moraxella spp.* have been found associated with the inflammation (Radostits et al., 1994). Treatments that
80 include HOCl are solutions, washes, teat dips and gels. They may be buffered or osmotically balanced.
81 HOCl is used at a relatively low concentration in these treatments, 0.01-0.02%.

82 **Approved Legal Uses of the Substance:**

83 Veterinary HOCl solutions are regulated by the US Food and Drug Administration (FDA) through the
84 premarket notification or 510 (k) programs. The procedure for 510 (k) submission is listed at
85 §21 CFR 807.21. The 510(k) is a manufacturer's self-certification of the safety and efficacy of the product
86 that otherwise does not require licensing. The FDA reviews and evaluates the product and determines 1)
87 that a premarket approval is necessary or 2) that a premarket approval is not required. After the
88 determination is made a letter is sent to the applicant allowing the product to be marketed. Solutions of
89 hypochlorous acid for use in treatment of eye irritation and wound care are already legally marketed. New
90 products such as those mentioned in the petition are considered substantially equivalent by the FDA and
91 do not require premarket approval.

92 A petition has been received by the USDA to add veterinary HOCl solutions for organic livestock
93 production to the National List.

94 **Action of the Substance:**

95 Neutrophils are white blood cells involved in the mammalian antibacterial immune response. They contain
96 an enzyme called myeloperoxidase that reacts with hydrogen peroxide also produced by the neutrophil at
97 sites of bacterial infection. Myeloperoxidase catalyzes the formation of hypohalous acids from hydrogen
98 peroxide (Mika and C, Guruvayoorappan, 2011). HOCl is the major product. It is antimicrobial in vitro,
99 although the actual antimicrobial process requires the conversion of HOCl to chloramine T which serves as
100 the antimicrobial reactive oxidative species. Chloramine T forms when HOCl reacts with amine groups
101 (Amulic et al., 2012).

102 HOCl rapidly kills the causative agents of infectious keratoconjunctivitis, wound infections and mastitides
103 (Gard et al. 2012; Amulic et al., 2012). In addition to its microbiocidal effect, HOCl can have an anti-
104 inflammatory effect by 1) reducing histamine activity, 2) reducing leukotriene activity, 3) increasing TGF-
105 beta activity, 4) increasing growth factor synthesis and 5) decreasing metalloprotease 7, collagenase and
106 gelatinase activity (Pelgrift and Friedman, 2013).

107 **Combinations of the Substance:**

108 Commercially available treatments contain products from the production of electrolyzed water, including
109 sodium chloride (NaCl), HOCl and sodium hypochlorite, but may also contain added pH buffers such as
110 sodium phosphate (NaH₂PO₄/ Na₂HPO₄), sodium sulfate and sodium bicarbonate, and colloidal gels such
111 as lithium magnesium sodium silicate depending upon the tissue to be treated. A teat dip product that
112 releases HOCl consists of two dissolved 2.5 g sodium dichloroisocyanurate tablets dissolved in one liter of
113 water with an available chlorine concentration of 2800 ppm at pH 5.5-6.0 (Bodie et al., 1995).

114 **Limited Scope Questions for Hypochlorous Acid to be Used Livestock Production**

115 For this limited scope report, the NOSB Livestock Subcommittee has requested that the report respond to
116 the specific questions listed below.

117

118 **Evaluation Question #1: What is the efficacy of hypochlorous acid for pinkeye and wound treatment,** 119 **relative to other products (both synthetic and on the National List)?**

120 HOCl is available in several commercial presentations for veterinary treatment of pink eye and wounds. A
121 number of studies with these preparations have shown the efficaciousness of HOCl for pinkeye, wounds,
122 burns and mastitides (Gard et al., 2016; Pegrft and Friedman, 2013; Hua et al., 2003). In addition to HOCl
123 and hypochlorite, these products can contain sodium phosphate or silicate in the case of colloidal burn

124 treatments. HOCl and hypochlorite salts are not currently on the National List for treatment of pink eye
125 and wounds. Sodium phosphates and aqueous potassium silicate are approved for use respectively in
126 organic handling (§205.605(b) and crop production (§205.601(e)(2)). Sodium phosphate or sodium silicate
127 may be allowed as excipients if their use complies with the requirements at section 205.603(f).

128 HOCl is a chlorine releasing agent (CRA). It is considered the active moiety responsible for bacterial
129 inactivation by CRAs. CRA microbiocidal activity is greatest when the percentage of undissociated HOCl is
130 highest. At a concentration of 50 micromoles (μM)/liter (l) (2.6 ppm), HOCl produces deleterious effects on
131 bacterial DNA resulting in the formation of chlorinated derivatives of nucleotide bases and complete
132 inhibition of *Escherichia coli* growth. Concentrations greater than 5 millimoles/l (260 ppm) have been found
133 to disrupt oxidative phosphorylation and other membrane-associated activity (McDonnell and Russell,
134 1999).

135 The primary cause of infectious bovine keratoconjunctivitis (pinkeye) is the bacteria *Moraxella bovis*. It is a
136 gram negative, aerobic, oxidase positive diplococcus (Holt, 1994). The bacterial pili and the enzyme
137 hemolysin have both been established in disease pathogenesis. The pili help to attach bacteria to the
138 cornea, while hemolysin is linked to cell membrane disruption. In addition, the host immune response
139 against the bacteria can be prolonged due to an immunoevasive process called phase variation. Phase
140 variation permits the bacterial to rearrange its genes for pilus formation producing a changing immune
141 signature for the largest bacterial organelle. Without a solid short term, immune response from the animal
142 pinkeye can be exacerbated and prolonged (Marrs et al., 1988). Vaccines used for pink eye must contain all
143 of the variant pilus types to be effective, thus many bacterins or killed vaccines commonly used in organic
144 production are not always effective (McConnell et al., 2008; O'Conner et al., 2011). However, without other
145 treatment options, many organic producers still choose to vaccinate. Vaccines are on the National List at
146 section 205.603(a)(4) as "Biologics - Vaccines."

147 A commercial veterinary spray treatment containing 0.009% HOCl, sodium chloride and phosphate buffer
148 was examined by a group at Auburn University. The study consisted of thirty calves randomized into three
149 groups. In groups one and two a corneal lesion was also induced into the left eye and the same eye was
150 then infected with *Moraxella bovis* to induce pinkeye. The right eye of these two groups served as a control.
151 No corneal lesion was induced. Nor was it infected with *M. bovis*. A third group did not receive a corneal
152 lesion in either eye, but was inoculated with *M. bovis* in the left eye. Beginning 24 hours after inoculation
153 with *M. bovis*, calves in group 1 were treated with 0.009% HOCl for a total of 2 milliliters per application (3
154 sprays) twice daily for ten days. Calves in group 2 were treated 24 hour post *M. bovis* inoculation with 0.9%
155 sterile saline solution for a total of 2 milliliters per application (3 sprays) twice daily for ten days. Following
156 inoculation with *M. bovis*, calves in group three were not treated. Both eyes in all three groups were
157 evaluated for evidence of pain and ocular discharge associated with the clinical signs of infectious bovine
158 keratoconjunctivitis (IBK) throughout the study. In addition, blood and liver biopsy samples were collected
159 to determine if chlorine levels increased internally. All calves in groups one and two developed corneal
160 ulcerations and clinical signs consistent with IBK in the left eye. No clinical signs were observed at any
161 time during the study in group three or the right eye of groups one and two. After ten days, all of the
162 animals in groups one and three were culture negative for *M. bovis*. Average healing time of corneal lesions
163 was 3.7 ± 1.2 days for group one and 8.3 ± 3.7 for group 2 ($p < 0.0002$). In this study, topical ophthalmic
164 application of HOCl was effective in treating experimentally induced pinkeye. No additional chlorine
165 accumulated internally in any of the test animals. Pain experienced by the calves as a result of the pinkeye
166 infection was also much less in the group treated with HOCl (Gard et al., 2016).

167 There are a number of studies in both human and rat showing positive results for healing and pain relief
168 from the use of HOCl solutions for debridement and maintenance of burns and wounds (Selkon et al.,
169 2006; Liden, 2013; Robson, 2007; Nakae and Inaba, 2000; Hua et al., 2003; Sakarya et al., 2014). In the case of
170 colorectal surgery, however; in which no significant difference was observed between using HOCl and
171 saline, HOCl is not recommended (Takesue et al., 2011). When used for veterinary wound treatment,
172 solutions containing a low concentration (0.11-0.12 %) of HOCl produced either by electrolysis of water or
173 dilution of sodium hypochlorite (Dakin's solution) provided a reduction in bacterial infection and
174 improved wound healing (Krahwinkel and Boothe, 2006; Ramey and Kinde, 2015).

175 During wound healing, there is a pH shift from acidic, which is the pH of normal skin to slightly alkaline,
176 resulting from the myriad of biochemical reactions facilitating degradation of dead tissue, the intercalation

177 of the wound with new structures of extracellular matrix and the reassembly of connective tissue and
178 epithelium (Schneider et al., 2007). The intervention of phagocytic white blood cells (neutrophils) during
179 this process includes the release of a chlorine to kill bacteria and fungi. An acidic pH adjustment also
180 occurs during this particular step which favors myeloperoxidase mediated production of the chlorine
181 releasing agent, HOCl (Pullar et al., 2000). Cellular antioxidants are produced to control excessive HOCl
182 production and prevent tissue damage (Mika and Guruvayoorappan C, 2011).

183 **Evaluation Question #2: What items are being used for pink eye and wound treatment on organic**
184 **farms?**

185 Face flies are known to carry and transmit the bacteria *Moraxella bovis*, the etiological agent for infectious
186 bovine keratoconjunctivitis (Berebile and Webber, 1981; OConnor et al., 2012). Controlling flies helps to
187 reduce the risks of disease spread between animals in a herd. The face fly, *Musca autumnalis* (Diptera:
188 Muscidae), feeds at the eyes and faces of cattle and horses in the temperate regions of the northern
189 hemisphere. Feeding flies probe with their proboscis and consume secretions or discharges from their
190 hosts' eyes, nostrils, mouths, vulvae, teats, and other body parts. Sharp spines surrounding the fly's mouth
191 may cause superficial lesions increasing the likelihood of infection. Eggs and larvae occur exclusively in the
192 dung pats of cattle and bison (Krafsur and Moon, 1997). Pinkeye was enzootic in North America before the
193 face fly was introduced, but its prevalence has increased since the fly arrived. Face fly abundance correlates
194 positively with disease incidence (Hall, 1984). Face flies are attracted to a number of substances including
195 cattle fed a diet of alfalfa (Pickens and Miller, 1980). Vespid wasps such as *Vespula germanica* (Fabricius)
196 have been identified as a predator of face flies. These and other predatory wasps can also be used to control
197 maggot fly larvae in dung (Schidtmann, 1977; Skovgard, 2004). Ground phosphate rock can be scattered
198 over gutter manure and manure heaps to destroy fly larva (Surface, 1915). Fly traps can be used for
199 removal of flies from the animals or their housing (Denning et al, 2014; Kaufman et al., 2005). Other organic
200 production methods for fly control can include the use of cow masks, cleaning out box stall buildup
201 (especially the near the corners), having chickens peck away the manure paddies after animals have been
202 through a paddock and/or having hogs root through the paddies. Frequent applications of extracts, and
203 essential oils as well as sulfur dusting may also provide some relief (An M.R.C.V.S., 1915).

204 Flies are generally more numerous in tall grass. Trimming tall grass, and foxtails can serve to reduce fly
205 populations (Bersford and Sutcliffe, 2008). Trimming tall grass also help to prevent scratches to the eyes of
206 feeding animals. Reducing moisture in the animal's environment helps to reduce fly numbers. Sprinkling
207 field lime or diatomaceous earth on the animals helps to keep them dry. Because pinkeye is infectious
208 affected animals should be separated if possible. However, in some cases, *M. bovis* may infect animals in a
209 carrier state where no clinical signs appear, but the animal remains infectious and bacterial transmission is
210 possible. Here diagnosis is important.

211 Topical treatment is recommended for both pinkeye and wounds. Repeated and frequent applications of
212 various combinations of isotonic saline solution, calendula, garlic, echinacea, cochlearia, honey (wounds),
213 sugar (wounds), essential oils, eyebright, goldenseal, colloidal silver, breast milk cod liver oil, *Aloe vera* and
214 coconut oil have been used as washes and topical treatments (Zinke, 2010; Menendez et al., 2007; Swaim
215 and Lee, 1987). Many of these substances are microbiocidal and serve to kill or control the bacterial
216 infection (Calvo and Czvero, 2016). For pinkeye, anything that soothes the eye is also helpful. Dairy cattle
217 and calves are generally easier to treat, since restraint may be required for application. No one method is
218 preferable and efficacy is not assured. In the case of wounds, and in addition to washing the wound,
219 disinfection is generally indicated (Krahwinkel and Boothe, 2006).

220 Kelp meal is often fed to organic dairy cattle serving as a mineral and vitamin source (Hardie et al., 2014)).
221 In addition, vitamins A, D, and E are helpful in maintaining the livestock immune system and eye health
222 (Anonymous, 1976). Adequate levels of trace minerals such as copper and selenium are also indicated for a
223 properly functioning immune system. Because sunlight and ultraviolet light aggravates pinkeye, animals
224 should be sequestered from sunlight and ultraviolet. It is best to let them out at night for grazing if this is
225 possible.

226 As of April 5, 2017, seven licensed *M. bovis* bacterin vaccines, one conditionally licensed *M. bovoculi*
227 bacterin vaccine, three combination bacterin-toxoid vaccines containing *M. bovis*, one *M. bovis* bacterin for
228 further manufacture and one *M. bovis* killed culture for further manufacture are listed in the USDA Animal
229 Plant Health Inspection Service's [USDA Veterinary Biological Products](#). These are also listed in Table 2.

230 Bacterins are normally acceptable for use in Organic Livestock Production. Bacterins are simply bacteria
 231 killed with formaldehyde. The formaldehyde is dried off, and an adjuvant is added to stimulate the
 232 immune response. Bacteria used for the bacterin may be a naturally occurring isolate or it may be
 233 genetically modified. Because *M. bovis* exhibits phase variation, several isolates are combined into the
 234 vaccine to cover possible immune variation. Furthermore, *M. bovoculi* was recently recognized as an
 235 additional causal bacterium for bovine pinkeye. A vaccine for this *M. bovoculi* is now also available
 236 (OConnor et al., 2012). Vaccines are a useful tool for reducing production losses (McConnel et al., 2008).
 237 However, the highly variable immunogenic profile of *M. bovis* has complicated the use of vaccines. Many
 238 producers use them, but they do not always work. Even a vaccine produced from isolates from the same
 239 farm where it was used was not very efficacious, raising a concern that even autogenous vaccines are often
 240 ineffective in controlling naturally occurring IBK (OConnor et al., 2011). Vaccinations should be
 241 administered well in advance (ideally at least four weeks) of the anticipated summer onset of pinkeye, so
 242 that cattle will have enough time to mount an effective immune response following vaccination. Young
 243 animals tend to be most affected, and should be a part of the vaccination program.

244

Table 2 Vaccines for Infectious Bovine Keratoconjunctivitis			
Type of Vaccine	USDA Vaccine Code	Producer	Description
<i>Moraxell bovis</i> bacterin	2772.00	1, 2, 3, 4	Formaldehyde inactivated, multiisolate bacterin. Contains an adjuvant to stimulate the immune response. Different isolates, numbers of isolate, adjuvants, etc.
	2772.03	5	
	2772.04	5	
	2772.10	6	
<i>Moraxella bovoculi</i> bacterin	2A77.00	4	For pinkeye caused by <i>M. bovoculi</i>
Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D-Moraxella Bovis Bacterin-Toxoid	7425.01	1	Multi valent bacterin-toxoid vaccine, contains <i>M. bovis</i> bacterin.
	7425.02	5	
	7425.03	5	
<i>Moraxell bovis</i> bacterin	B772.00	4	for further manufacture
<i>Moraxell bovis</i> killed culture	B772.01	4	
<p>¹Boehringer Ingelheim Vetmedica, Inc., Divisions: Bio-Ceutic, Anchor, 2621 North Belt Highway, St. Joseph, MO 64506 (124, 124A)</p> <p>²Elanco US Inc. 196, Subsidiaries: Lohmann Animal Health International, Elanco US Inc., 1447 140th Street, Larchwood, IA 51241, 196</p> <p>³Novartis Animal Health US, Inc., 1447 140th Street, Larchwood, IA 51241-9778 303</p> <p>⁴Addison Biological Laboratory, Inc., Route 3 Box 90-B, Fayette, MO 65248 355</p> <p>⁵Intervet Inc. 165A, Divisions: Merck Animal Health, Merck Sharpe and Dohme (MSD), 21401 West Center Road, Elkhorn, NE 68022</p> <p>⁶SolidTech Animal Health, Inc. 604, 812 NE 24th Street, P.O. Box 790, Newcastle, OK 73065-0790</p>			

245

246 Hair color, age, host behavior such as comparisons of movement, grazing and lying down and aggregation
247 of host animals have been reported to influence cattle-host selection by face flies and predilection for
248 pinkeye. Breeds which lack pigment on their eyelids (Herefords, Hereford crosses, Charolais and some
249 Holsteins) are hypothesized to be more susceptible to pinkeye than dark-hided cattle. Although lighter hair
250 and eye color suggests more susceptibility, hair color and eye pigment are likely not to be the only selective
251 criteria. The breed that appears to be most susceptible to face flies and pinkeye is the Hereford. While
252 tropically adapted breeds such as Brahmin are less susceptible. (Steelman et al., 1993, Snowden et al., 2005).

253 Genetic tracking of breed susceptibility to pinkeye has followed the quantitative trait locus (QTL). A QTL is
254 a section of genetic information (DNA) on a chromosome (the locus) in the genome that correlates with
255 variation in a phenotype (the quantitative trait). Usually the QTL is nearby on the chromosome, or
256 contains, the genes that control the specific phenotype. QTLs are mapped by identifying the molecular
257 biomarkers correlated with an observed trait. This is sometimes an early step in identifying and sequencing
258 the actual genes that cause the trait variation (Miles and Wayne, 2008). QTLs have been identified for
259 infectious bovine keratoconjunctivitis (IBK) on chromosome 1 and 20 associated with the probability of
260 contracting this disease (Casa and Stone, 2006). The QTL on chromosome 1 may have a link to the bovine
261 macrophage activity, while the QTL on chromosome 20 may be associated with the cellular or non-specific
262 immune response (Garcia et al., 2010; Casa and Stone, 2008).

263 Wound care begins with direct pressure to the wounded site. This helps to stop the bleeding. Ice also
264 constricts vessels and will slow bleeding. Irrigation with saline, dilute disinfectant or water is next to wash
265 away contamination including bacteria and stimulate healing. Both iodine and chlorhexidine are allowed
266 for use as disinfectants when other disinfection methods are not expected to work. Iodine is allowed for
267 use as a disinfectant and a topical treatment. Aqueous iodine is antibacterial, but at higher concentration is
268 deleterious to tissues *in vivo* and may potentiate infection. Iodine is more effective at lower concentrations,
269 0.1% or 1%, rather than the 10% solution that is normally supplied (Swaim and Lee, 1987). Chlorhexidine is
270 allowed for surgical procedures conducted by a licensed veterinarian. Chlorhexidine is an effective
271 antimicrobial. Wounds irrigated with 0.1%, 0.25% or 1% chlorhexidine did better than wounds respectively
272 irrigated with 0.1%, 0.25% and 0.5% iodine and polyvinylpyrrolidone. However, a correlation between
273 chlorhexidine use and joint inflammation has been noted. Although not approved for organic use, Dakin's
274 solution, a dilute sodium hypochlorite solution (0.005%) has been found to be more effective at killing
275 *Staphylococcus aureus* than chlorhexidine (Swain and Lee, 1987). Externally copper sulfate is antiseptic,
276 astringent, caustic germicidal, fungicidal and viricidal. It can be used in solution for wound debridement
277 and applied as a powder to wounds and as an antiseptic post surgical treatment (Mouli, 2005). Ringer's
278 solution is effective for wound debridement and some relief from pain (Colegrave et al., 2016). Ringer's
279 solution typically contains sodium chloride, potassium chloride, calcium chloride and sodium bicarbonate,
280 with the last used to balance the pH.

281 **Evaluation Question #3: What natural items could be used?**

282 Natural items are products that come from plants, animals, or minerals. There are many remedies that have
283 not been experimentally tested. Several organically produced combinations are available commercially.
284 Table 3 provides a non-exhaustive list of known natural products that may be used in pinkeye and/or
285 wound treatment. Many of these treatments may be used under veterinary supervision. While others can
286 be practically applied without a veterinarian's help.

287 **Evaluation Question #4: What does the National List currently allow for pink eye and wound treatment?**

289 One of the most compelling aspects of organic farming is system health. Organic health management
290 includes the creation of a complete system for sustainable livestock welfare minimizing vectors of disease
291 and ensuring livestock are provided proper nutrition and environment to build a strong natural immune
292 repertoire when stress and pathogens occur (Coffey and Baier, 2012). Water washing, and isotonic saline
293 washing are allowed for organic livestock production. Non-synthetic (natural) herbal microbiocide
294 decoctions are not specifically listed in the National List, but are allowed in Organic Livestock production.
295 Ethanol and isopropanol are permitted as topical disinfectants (7 CFR 205.603(a)(1)(i)) and can be used for
296 wound care. Chlorhexidine is also indicated and allowed for surgical procedures conducted by a
297 veterinarian (7 CFR 205.603(a)(6)). Biologics— Vaccines (7 CFR 205.603(a)(4)) for pinkeye are allowed for
298 organic livestock production. For wound care, both hydrogen peroxide hydrogen peroxide (7 CFR

Table 3 Natural substances used for pinkeye and wound treatment		
<u>Plant or substance</u>	<u>Classification Nomenclature</u>	<u>Application</u>
Seabuckthorn	<i>Hippophae rhamnoides</i>	Wounds ³
Parasitic wasps	<i>Spalangia cameroni</i>	Pinkeye ³
Kiwi fruit	<i>Actinidia deliciosa</i>	Wounds ⁸
Aloe	<i>Aloe vera</i>	Pinkeye, wounds ^{1,4,5}
Calendula	<i>Calendula officinalis</i>	Pinkeye ¹
Chamomile	<i>Chamoemelum nobile</i>	Pinkeye ¹
Chicory	<i>Cichorium intybus</i>	Pinkeye ¹
St. John's Wort	<i>Hypericum perforatum</i>	Pinkeye ¹
Olive	<i>Olea europaea</i>	Pinkeye ¹
White poplar	<i>Populus alba L.</i>	Pinkeye ¹
Rose	<i>Rosa agrestis</i>	Pinkeye ¹
Elder	<i>Sambucus nigra L. ssp. nigra</i>	Pinkeye ¹
Navelwort	<i>Umbilicus rupestris</i>	Pinkeye ¹
Mullein	<i>Verbascum sinuatum L.</i>	Pinkeye ¹
Veronica	<i>Veronica spp.</i>	Pinkeye ¹
Physic nut	<i>Jatropha curcas</i>	Wounds ⁶
Bacterial predators	<i>Bdellovibrio bacteriovorus</i>	Pinkeye ²
Brown kelp alginates	<i>Ascophyllum nodosum</i>	Wounds ⁵
Honey	---	Wounds ⁵
Sugar	---	Wounds ⁵
Pineapple Fruit Enzymes (bromelain)	<i>Ananas comosus</i>	Wounds ⁷
Omentum	---	Wounds ⁵
Chitosan	---	Wounds ⁵
Platelet Gel	---	Wounds ⁵
Pink Trumpet Tree	<i>Tabebuia avellanediae</i>	Wounds ⁹
Brazilian Pepper Tree	<i>Schinus terebinthifolius</i>	Wounds ⁹
Siam Weed	<i>Chromolaena odorata</i>	Wounds ¹⁰
¹ Calvo and Caverio, 2016; ² Boileau et al., 2011; ³ Skovgard, 2004; ⁴ Swaim and Lee, 1987; ⁵ Krahwinkel, D.J. and Boothe; ⁶ Thomas et al., 2008; ⁷ Rosenberg et al., 2004; ⁸ Hafzei et al., 2010; ⁹ Lipinski et al., 2012; ¹⁰ Vijayaraghavan et al., 2017.		

299 205.603(a)(11)) and iodine (7 CFR 205.603(a)(14)) are allowed. In addition, vitamins (7 CFR 205.603(d)(2))
300 and mineral supplements (7 CFR 205.603(d)(3)), e.g. vitamin A, D, and E, may be added the diet to improve
301 the immune response and the immune health of the eye. The producer of an organic livestock operation
302 must not withhold medical treatment from a sick animal in an effort to preserve its organic status. All
303 appropriate medications must be used to restore an animal to health when methods acceptable to organic
304 production fail. Livestock treated with a prohibited substance must be clearly identified and shall not be
305 sold, labeled, or represented as organically produced (7 CFR 205.238(c)(7)).

References

- 307 Amulic, B., Cazalet, C., Hayes, G.L., Metzler, K.D. and Zychlinsky, A. (2012) Neutrophil function: from
308 mechanisms to disease, *Annu. Rev. Immunol.*, 30, pp. 459-489.
- 309 An M.R.C.V.S. (1915) *The Farm Vet*, McDonald and Martin, London.
- 310 Anonymous (1976) More minerals and vitamin A, less face flies: check pinkeye, *Livestock Breeders Journal*,
311 19:7, pp. 177-179.
- 312 Beresford, D.V. and Sutcliffe, J.F. (2008) Stable fly (*Stomoxys calcitrans*: Diptera, Muscidae) trap response to
313 changes in effective trap height caused by growing vegetation, *Journal of Vector Ecology*, 33:1, pp. 40-45.
- 314 Berkebile, D.R, Hall, R.D. and Webber, J.J. (1981) Field association of female face flies with *Moraxella bovis*,
315 an etiological agent of bovine pinkeye, *J. Economic Entomology*, 74:4, pp. 475-477.
- 316 Black and Veatch Corporation (2011) *White's Handbook of Chlorination and Alternative Disinfectants*,
317 John Wiley and Sons.
- 318 Bodie, R.L., Nickerson, S.C., Doyle, M.G., and McGuire, H.J. (1995) Efficacy of a new hypochlorous acid-
319 releasing teat dip against *Staphylococcus aureus* and *Streptococcus agalactiae* under conditions of experimental
320 challenge, *National Mastitis Council Meeting Proceedings*, 34, pp. 156-157.
- 321 Boileau, M.J., Clinenbeard, K.D. and Iandolo, J.J. (2011) Assessment of *Bdellovibrio bacteriovirus* 109J killing
322 of *Moraxella bovis* in an *in vitro* model of infectious bovine keratoconjunctivitis, *The Canadian Journal of*
323 *Veterinary Research*, 75, pp. 285-291.
- 324 Calvo, M.I. and Cavero, R.Y. (2016) Medicinal plants used for ophthalmological problems in Navarra
325 (Spain), *Journal of Ethnopharmacology*, 190, pp. 212-218.
- 326 Calvo, M.I. and Czvero, R.Y. (2016) Medicinal plants used for ophthalmological problems in Navarra
327 (Spain), *Journal of Ethnopharmacology*, 190, pp. 212-218.
- 328 Casas, E. and Stone, R. T. (2006) Putative quantitative trait loci associated with the probability of
329 contracting infectious bovine keratoconjunctivitis, *Journal of Animal Science*, 84:12, pp. 3180-3184.
- 330 Casas, E. and Stone, R. T. (2008) A putative quantitative trait locus on chromosome 20 associated with
331 bovine pathogenic disease incidence, *Journal of Animal Science*, 86, pp. 2455-2460.
- 332 Coffey, L. and Baier, A.H. (2012) [Guide for Organic Livestock Producers](#), ATTRA, National Center for
333 Appropriate Technology, USDA, NOP.
- 334 Colgrave, M., Rippon, M.G. and Richardson, C. (2016) The effect of Ringer's solution within a dressing to
335 elicit pain relief, *Journal of Wound Care*, 25:4, pp. 184-190.
- 336 Dakin, H.D. (1915a) On the use of certain antiseptic substances in the treatment of infected wounds, *British*
337 *Medical Journal*, 2:2852, pp. 318-320.
- 338 Dakin, H.D. (1915b) The antiseptic action of hypochlorites: the ancient history of the "new antiseptic,"
339 *British Medical Journal*, 2:2866, pp. 809-810.
- 340 Denning, S.S., Washburn, S.P. and Watson, D.W. (2014) Development of a novel walk-through fly trap for
341 the control of horn flies and other pests on pastured dairy cows, *J. Dairy Sci.*, 97, pp. 4624-4631.
- 342 Farley, H. (1941) Keratitis: the virulence, transmissibility and course of bovine 'pinkeye,' *Journal of the*
343 *American Veterinary Association*, 3, pp. 74-76

- 344 Garcia, M.D., Matukumalli, L., Wheeler, T.L., Shackelford, S.D, Smith, T.P.L., and E. Casas, E. (2010)
345 Markers on bovine chromosome 20 associated with carcass quality and composition traits and incidence of
346 contracting infectious bovine keratoconjunctivitis, *Animal Biotechnology*, 21, pp. 188–202.
- 347 Gard, J., Taylor, D., Maloney, R., Schnuelle, M., Duran, S., Moore, P., Justus, W., Walz, P., Stockle, R.,
348 Rodning, S., DeGraves, F., van Santen, E., Edmonson, M. and O’Conner, A.M. (2016) Preliminary
349 evaluation of hypochlorous spray for treatment of experimentally induced infectious bovine
350 keratoconjunctivitis, *The Bovine Practitioner*, 50:2, pp. 180-189.
- 351 Hafezi, F., Rad, H.E., Naghibzadeh, B., Nouhi, A. and Naghibzadeh (2010) Actinidia deliciosa (kiwifruit), a
352 new drug for enzymatic debridement of acute burn wounds, *Burns*, 36, pp. 352– 355.
- 353 Hall, R.D. (1984) Relationship of the face fly (Diptera: Muscidae) to pinkeye in cattle: a review and
354 synthesis of the relevant literature, *J. Med. Entomol.*, 21, pp. 361–365.
- 355 Hardie, C.A., Wattiaux, M., Dutreuil, M. Gildersleeve, R. Keuler, N.S. and Cabrera, V.E. (2014) Feeding
356 strategies on certified organic dairy farms in Wisconsin and their effect on milk production and income
357 over feed costs, *J. Dairy Sci.*, 97, pp. 4612-4623.
- 358 Holt, J.G. (1994) *Bergey’s Manual of Determinative Bacteriology*, LWW.
- 359 Hua, X., Zheng, Y-J., Nakae, H. and Han, Z-G (2003) Effect of electrolyzed oxidizing water and
360 hydrocolloid dressings on excised burn-wounds in rats, *Chinese J. Traumatology*, 6:4, pp. 234-237.
- 361 Hua, X., Zheng, Y-j., Nakae, H. and Han, Z-G. (2003) Effects of electrolyzed oxidizing water and
362 hydrocolloid occlusive dressings on excised burn-wounds in rats, *Chinese Journal of Traumatology*, 6:4,
363 pp.234-237.
- 364 Kaufman, P.E., Rutz, D.A. and Frisch, S. (2005) Large Sticky Traps for Capturing House Flies and Stable
365 Flies in Dairy Calf Greenhouse Facilities, *J. Dairy Sci.*, 88, pp. 176–181.
- 366 Kettle, A.J., Albrecht, A.M., Chapman, A.L., Dickerhof, N., Forbes, L.V., Khalilova, I. and Turner, R. (2014)
367 Measuring chlorine bleach in biology and medicine, *Biochimica et Biophysica Acta*, 1840, pp. 781–793.
- 368 Kidwell, B. (2016) Put an end to pinkeye, [Progressive Farmer](#), March.
- 369 Krafur, E.S. and Moon, R.D. (1997) Bionomics of the face fly, *Musca autumnalis*, *Annu. Rev. Entomol.*, 42,
370 pp. 503–523.
- 371 Krahwinkel, D.J. and Boothe, H.W. (2006) Topical and systemic medications for wounds, *Vet. Clinics. Small*
372 *Anim.*, 36:4, pp. 739-757.
- 373 Krahwinkel, D.J. and Boothe, H.W. (2006) Topical and systemic medications for wounds, *Vet Clinics Small*
374 *Anim.*, 36, pp. 739-757.
- 375 Liden, B.A. (2013) Hypochlorous Acid: Its Multiple Uses for Wound Care, *Ostomy Wound Management*,
376 September, pp. 8-10.
- 377 Lipinski, L.C., Wouk, P.D.F., de Silva, N.L., Perotto, D. and Ollhoff, R.D. (2012) Effects of 3 Topical Plant
378 Extracts on Wound Healing in Beef Cattle, *Afr J Tradit Complement Altern Med.*, 9:4, pp. 542-547.
- 379 Marrs, C.F., Ruehl, W.W., Schoolnik, G.K. and Falkow, S. (1988) Pilin gene phase variation of *Moraxella*
380 *bovis* is caused by an inversion of the pilin genes, *Journal of Bacteriology*, 170:7, pp. 3032-3039.
- 381 McConnell, C.S., Shum, L., Gleeson, B.L. and House, J.K. (2008) Serologic cross-reactivity of Australian
382 McConnell, C.S., Shum, L., Gleeson, B.L. and House, J.K. (2008) Serologic cross-reactivity of Australian,
383 *Moraxella bovis* to vaccinal bacterin strains as determined by competitive ELISA, *Australian Veterinary*
384 *Journal*, 86:4, pp. 124-129.
- 385 McDonnell, G. and Russell, A.D. (1999) Antiseptics and Disinfectants: Activity Action and Resistance, 12:1,
386 pp. 147-179.
- 387 Menendez, A.B., Parra, A.L., Pavon, V.B., Dominguez, C.C., Martinez, O.V. Sardinias, I.G. and Munoz, A.
388 (2007) Actividad Cicatrizante y Ensayos de Irritación de la Crema de Calendula officinalis al 1%, *Lat. Am. J.*
389 *Pharm.*, 26:6, pp. 811-817.

- 390 Mika, D. and Guruvayoorappan C. (2011) Myeloperoxidase: the yin and yang of tumour progression,
391 Journal of Experimental Therapeutics and Oncology, 9, pp. 93-100.
- 392 Mika, Denish and C, Guruvayoorappan (2011) Myeloperoxidase: the yin and yang in tumor progression,
393 Journal of Experimental Therapeutics and Oncology, 9, pp. 93-100.
- 394 Miles, C.M. and Wayne, M. (2008) Quantitative Trait Locus (QTL) Analysis, Scitable, Nature Education, 1,
395 pp. 1-4.
- 396 *Moraxella bovis* to vaccinal bacterin strains as determined by competitive ELISA Australian Veterinary
397 Journal, 86:4, pp.124-129.
- 398 Mouli, S.P. (2005) Copper sulphate in veterinary practice, Indian J. Vet Surg., 26:1, pp. 57-58.
- 399 Nakae, H. and Inaba (2000) Effectiveness of Electrolyzed Oxidized Water Irrigation in a Burn-Wound
400 Infection Model, J Trauma, 49, pp. 511-514.
- 401 National Center for Biotechnology Information—NCBI (2017) Hypochlorous Acid, PubChem Compound
402 Database; CID=24341, <https://pubchem.ncbi.nlm.nih.gov/compound/24341> (accessed June 5, 2017).
- 403 O’Conner, A.M., Brace, S., Gould, S., Dewell, R. and Engelken, T. (2012) A randomized clinical trial
404 evaluating a farm-of-origin autogenous *Moraxella bovis* vaccine to control infectious bovine
405 keratoconjunctivis (Pinkeye) in beef cattle, J Vet Intern Med, 25, pp. 1447-1453.
- 406 OConnor, A.M., Brace, S., Gould, S., Dewell, R. and Engelken, T. (2011) A Randomized Clinical Trial
407 Evaluating a Farm-of-Origin Autogenous *Moraxella bovis* Vaccine to Control Infectious Bovine
408 Keratoconjunctivitis (Pinkeye) in Beef Cattle, J Vet Intern Med, 25, pp. 1447-1453.
- 409 OConnor, A.M., Shen, H.G., Wang, C. and Opriessnig, T. (2012) Descriptive epidemiology of *Moraxella*
410 *bovis*, *Moraxella bovoculi* and *Moraxella ovis* in beef calves with naturally occurring infectious bovine
411 keratoconjunctivitis (Pinkeye), Veterinary Microbiology, 155, pp. 374-380.
- 412 OConnor, A.M., Shen, H.G., Wang, C. and Oriessnig, T. (2011) Descriptive epidemiology of *Moraxella*
413 *bovis*, *Moraxella bovoculi* and *Moraxella ovis* in beef calves with naturally occurring infectious bovine
414 keratoconjunctivitis (Pinkeye), Veterinary Microbiology, 155, pp. 374-380.
- 415 Pegrifi, R.Y. and Friedman, A.J. (2013) Topical hypochlorous acid (HOCl) as a potential treatment of
416 pruritus, Curr Derm Rep, 2, pp. 181-190.
- 417 Pickens, L.G. and Miller, R.W. (1980) Biology and control of the face fly, *Musca autumnalis*
418 (Dipter:Muscidae), J. Med. Entomology, 17:3, pp. 195-210.
- 419 Pullar, J.M., Vissers, M.C.M. and Winterbourn, C.C. (2000) Living with a Killer: The Effects of
420 Hypochlorous Acid on Mammalian Cells, Life, 50, pp. 259-266.
- 421 Ramey, D.W. and Kinde, H. (2015) Commercial and Homemade Extremely Dilute Hypochlorous Acid
422 Solutions Are Bactericidal Against *Staphylococcus aureus* and *Escherichia coli* In Vitro, Journal of Equine
423 Veterinary Science, 35, pp. 161-164.
- 424 Robson, M.C., Payne, W.G., Ko, F.K., Mentis, M., Donati, G., Shafi, S.M., Culverhouse, S., Wang, L. Khosrovi,
425 B., Najafi, R., Cooper, D.M. and Bassiri, M. (2007) Hypochlorous Acid as a Potential Wound Care Agent,
426 Part II. Stabilized Hypochlorous Acid: Its Role in Decreasing Tissue Bacterial Bioburden and Overcoming
427 the Inhibition of Infection on Wound Healing, Journal of Burns and Wounds, 6, pp. 80-90.
- 428 Rosenberg, L., Lapid, O., Bogdanov-Berezovsky, Glesinger, R., Krieger, Y. Silberstein, E., Sagi, A. Judkins,
429 K. and Singer, A.J. (2004) Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a
430 preliminary report, Burns, 30, pp. 843-850.
- 431 Sakarya, S., Gunay, N., Karakulak, M. Ozturk, B. and Ertugrul, B. (2014) Hypochlorous Acid: An Ideal
432 Wound Care Agent With Powerful Microbicidal, Antibiofilm, and Wound Healing Potency, Wounds,
433 26:12, pp. 342-350.
- 434 Sakarya, S., Gunay, N., Meltem, K., Ozturk, B. and Ertugrul, B. (2016) Hypochlorous Acid: An ideal wound
435 care agent with powerful, antibiofilm, and wound healing potency, 26:12, pp. 342-350.

- 436 Schneider, L.A., Korber, A., Grabbe, S. and Dissemond, J. (2007) Influence of pH on wound-healing: a new
437 perspective for wound-therapy? Arch Dermatol Res, 298, pp. 413-420.
- 438 Selkon, J.B., Cherry, G.W., Wilson, J.M. and Hughes, M.A. (2006) Evaluation of hypochlorous acid washes
439 in the treatment of chronic venous leg ulcers, Journal of Wound Care, 15:1, pp. 33-37.
- 440 Skovgard, H. (2004) Sustained releases of the pupal parasitoid *Spalangia cameroni* (Hymenoptera:
441 Pteromalidae) for control of house flies, *Musca domestica* and stable flies *Stomoxys calcitrans* (Diptera:
442 Muscidae) on dairy farms in Denmark, Biological Control, 30, pp. 288-297.
- 443 Snowden, G.D., van Vleck, L.D., Cundiff, L.V. and Bennet, G.L. (2005) Genetic and environmental factors
444 associated with incidence of infectious bovine keratoconjunctivitis in preweaned beef calves, Journal of
445 Animal Science, 83:3, pp. 507-518.
- 446 Steelman, C.D., Gbur, E.E., Tolley, G. and Brown, A.H. (1993) Variation in population density of the face
447 fly, *Musca autumnalis* de Geer, among selected cattle breeds of beef cattle, J. Agric. Entomol., 10:2, pp. 97-106.
- 448 Surface, H.A. (1915) To keep down house flies, Zool. Press bulletin, 313.
- 449 Swaim, S.F. and Lee, A.H. (1987) Topical Wound Medications: a review, Journal of the American
450 Veterinary Medical Association, 190:12, pp. 1588-1593.
- 451 Swaim, S.F. and Lee, A.H. (1987) Topical wound medications: a review, J. Amer. Veterinary Medical
452 Assoc., 12:15, pp. 1588-1593.
- 453 Takesue, Y., Takahashi, Y., Ichiki, K., Nakajima, K., Tsuchida, T. A., Uchino, M. and Ikeuchi, H. (2011)
454 Application of an Electrolyzed Strongly Acidic Aqueous Solution Before Wound Closure in Colorectal
455 Surgery, Diseases of the Colon and Rectum, 54: 7, pp. 826-832.
- 456 US Department of Agriculture, National Organic Program – US NOP (2015) [Policy Memo 15-4](#)
- 457 Vijayaraghavan, K., Rajkumar, J., Bukhari, S.N.A., Al-Sayed, B. and Seyed, M.A. (2017) *Chromolaena odorata*:
458 A neglected weed with a wide spectrum of pharmacological activities (Review), Molecular Medicine
459 Reports, 15, pp. 1007-1016.
- 460 White, G. C. (1972) Handbook of Chlorination. Van Nostrand Reinhold Company, New York.
- 461 Wiant, C. (2013) [The chlorine residual: A public health safeguard](#), Water Quality and Health Council.
- 462 Zinke, J. (2010) Treatment of conjunctivitis and conjunctival irritation in animals, Biologische tiermedizin,
463 27:1, pp. 17-25.